Palisade Bio Reports Early PALI-2108 IBD Signals as Phase 2 Studies Advance

In five Crohn’s patients, mean endoscopic activity fell 47.5% and fecal calprotectin fell 58.8% at 14 days. The company said its Phase 2b ulcerative colitis trial is enrolling and a Phase 2a Crohn’s study is being initiated.